Streetbeat News

Price Targets

HPE

Recent evaluations of Hewlett Packard (NYSE:HPE) by 5 financial analysts show a mix of opinions, with a shift towards a more cautious stance over the last three months. The average 12-month price target for HPE has been adjusted to $17.2, down from $18.20, reflecting a 5.49% decline. Analysts from firms including Morgan Stanley, Stifel, Wells Fargo, Evercore ISI Group, and Barclays have updated their ratings and price targets, indicating a nuanced view of HPE's market position amidst challenges in revenue growth and financial performance.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 8:00 pm

WAB

Recent analyst ratings for Westinghouse Air Brake (NYSE:WAB) show a predominantly positive outlook, with 6 analysts offering insights ranging from bullish to indifferent. The average 12-month price target for WAB has been raised to $152.83, indicating a 5.11% increase from the previous target. The company has shown solid revenue growth of 9.54% and a net margin of 8.51%, though its ROE at 2.07% is below industry standards. Its ROA at 1.14% and a low debt-to-equity ratio of 0.39 highlight strong financial health and efficient asset utilization.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 8:00 pm

LMND

Four analysts have recently updated their ratings and price targets for Lemonade (NYSE:LMND), showing a mix of opinions. The average 12-month price target is now $22.25, up from $14.50, indicating a 53.45% increase. Analysts' ratings range from 'Market Perform' to 'Underweight', with price targets varying from $14.00 to $40.00. Lemonade's financial performance shows a revenue growth of 30.66% over the past three months, but struggles with a net margin of -36.71% and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 7:01 pm

FCNCA

First Citizens BancShares (NASDAQ:FCNCA) received mixed analyst ratings with 2 bullish, 1 somewhat bullish, and 1 indifferent over the past three months. The average 12-month price target is $1788.5, reflecting a 10.27% increase from the previous target of $1622. Analysts from DA Davidson, Goldman Sachs, UBS, and Wedbush have adjusted their ratings and price targets, indicating a positive outlook on FCNCA's performance. The company has shown significant revenue growth, a high net margin, and strong ROE and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 7:01 pm

WFRD

Weatherford International (NASDAQ:WFRD) has been analyzed by 4 analysts, showing a mix of bullish and somewhat bullish ratings with an updated average 12-month price target of $151.25, indicating a 20.68% increase from the previous target. The company's financials reveal strong performance with a revenue growth rate of 12.66%, a net margin of 10.28%, and an ROE of 16.81%, despite a high debt-to-equity ratio of 2.23.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 7:01 pm

JRVR

James River Gr Hldgs (NASDAQ:JRVR) has received mixed analyst ratings with a notable decrease in the average price target by 37.5%, setting it at $12.5. Analysts from JMP Securities, Keefe, Bruyette & Woods, UBS, and Truist Securities have adjusted their ratings and price targets, reflecting a varied outlook on the company's performance. Despite a significant revenue growth of 58.93%, JRVR faces challenges with a net margin of -130.74%, ROE of -27.85%, and ROA of -2.91%, indicating potential profitability and efficiency issues.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 7:00 pm

MRNS

RBC Capital analyst Brian Abrahams downgraded Marinus Pharma (MRNS) from Outperform to Sector Perform and significantly reduced the price target from $24 to $3.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 6:52 pm

LLY

Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Eli Lilly and Co (LLY) with a maintained price target of $815.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 6:31 pm

REGN

Cantor Fitzgerald analyst Louise Chen has reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a $925 price target.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 6:29 pm

DG

JP Morgan analyst Matthew Boss maintains a Neutral rating on Dollar General (NYSE:DG) and raises the price target from $158 to $161.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 6:23 pm